Synaffix ADC Technology Enters the Clinic as Collaboration with ADC Therapeutics Advances
Lausanne, Switzerland, January 16, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I...
Synaffix Announces License Agreement with Mersana Therapeutics for the Use of its GlycoConnect™ Site-Specific ADC Technology
AMSTERDAM, NETHERLANDS – January 4, 2019 – Synaffix B.V. announced today it has entered into a license agreement with Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates...
BioGeneration Ventures’ portfolio company Staten Biotechnology announces collaboration with Novo Nordisk
BioGeneration Ventures (BGV) is pleased to announce that its portfolio company Staten Biotechnology B.V. and Novo Nordisk A/S have entered into a collaboration and exclusive option agreement. Under the collaboration agreement, Staten will continue to develop its lead...
Press Release NorthSea Therapeutics: Icosabutate latest data shows direct and potent anti-fibrotic effect in both differentiated rodent NASH models and human stellate cells.
Results to be presented at the AASLD congress 2018, 9-13 November In a biopsy-confirmed fibrotic ob/ob NASH mouse model, icosabutate reduced hepatic fibrosis in association with a 45% decrease in myofibroblast content in pre- versus post-treatment liver biopsies In a...
Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline
Maastricht, The Netherlands, 2nd November 2018 – Cristal Therapeutics, a clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, has appointed Dr. Axel Mescheder to the role...
Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer
Maastricht, The Netherlands, 25th October 2018 – Cristal Therapeutics, a clinical stage pharmaceutical company developing unique nanomedicines for the treatment of cancer and other diseases, announced today the first patient has been dosed in its Phase 2 clinical...
Escalier Doses First Patient with ESR-114 and Announces Clinical Advisory Board
Commences study to assess novel RORγt inhibitor for the treatment of psoriasis Recruits key opinion leaders to guide clinical development of its RORγt programs. NIJMEGEN, The Netherlands and Encinitas, California, August 13, 2018 – Escalier Biosciences, BV, a...
Azafaros B.V. secures seed funding to develop new treatments in rare metabolic disorders
Company to address unmet medical needs in the field of rare metabolic disorders Exclusive IP licensed from Leiden University and Amsterdam UMC Senior industry R&D leader Olivier Morand appointed as Chief Executive Officer and member of the Board of Directors...
VarmX raises €12.5 million to develop modified blood coagulation factor X for treating severe bleeding in patients using anticoagulants
Funding enables clinical stage trials of lead compound PseudoXa € 7.5 million Series A financing from lead investor BioGeneration Ventures (BGV) and Dutch regional development company InnovationQuarter Financing supplemented by € 5.0 million innovation credit from the...
Synaffix Further Strengthens Its Scientific Advisory Board with the Addition of John Lambert PhD, Former CSO of ImmunoGen
AMSTERDAM, NETHERLANDS – May 14, 2018 – Synaffix B.V. announced today the expansion of its Scientific Advisory Board (SAB) with the addition of Dr. John M. Lambert, the former Chief Scientific Officer of ImmunoGen, Inc. Dr. Lambert joined ImmunoGen Inc. in 1987 and...